Unfortunately, although MAT2A is indeed an excellent potential target for cancer therapy and multiple MAT2A inhibitors are identified in recent years, there still lacks the mature MAT2A inhibitor drug for the clinical application of the broad-spectrum cancers due to various shortages. Here, MAT2A is linked to cancer.